Key result
Review highlights the emerging pipeline and cardiovascular potential of next-generation obesity pharmacotherapy.
Weekly journal scan reveals advancements in obesity pharmacotherapy, indicating potential breakthroughs.
Journal Article Weekly Journal Scan: REDEFINing the next generation of obesity pharmacotherapy Get access Giovanna Liuzzo, Giovanna Liuzzo Department of Cardiovascular Medicine, Fondazione Policlinico Universitario A. Gemelli—IRCCS, Largo A. Gemelli 8, Rome 00168, ItalyDepartment of Cardiovascular and Pulmonary Sciences, Catholic University, School of Medicine, Largo F. Vito 1, Rome 00168, Italy Corresponding author. Emails: [email protected], [email protected], [email protected]. https://orcid.org/0000-0002-5714-0907 Search for other works by this author on: Oxford Academic PubMed Google Scholar Carlo Patrono Carlo Patrono Department of Cardiovascular and Pulmonary Sciences, Catholic University, School of Medicine, Largo F. Vito 1, Rome 00168, ItalyCenter of Excellence on Ageing, CAST, 'G. D'Annunzio' University School of Medicine Chieti 66013, Italy https://orcid.org/0000-0002-6447-2424 Search for other works by this author on: Oxford Academic PubMed Google Scholar European Heart Journal, ehaf628, https://doi.org/10.1093/eurheartj/ehaf628 Published: 19 September 2025 Article history Received: 02 August 2025 Accepted: 04 August 2025 Published: 19 September 2025
No takes yet. Share an insight, caveat, or question.
Liuzzo et al. (2025) conducted a review in Obesity. Obesity pharmacotherapy was evaluated. This weekly journal scan reviews the next generation of obesity pharmacotherapy.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: